224 related articles for article (PubMed ID: 35571340)
1. Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy.
Rajapakse P; Andanamala H
World J Oncol; 2022 Apr; 13(2):49-52. PubMed ID: 35571340
[TBL] [Abstract][Full Text] [Related]
2. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.
Sadaat M; Jang S
J Immunother Cancer; 2018 Jun; 6(1):49. PubMed ID: 29871698
[TBL] [Abstract][Full Text] [Related]
3. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
Liu LL; Skribek M; Harmenberg U; Gerling M
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36878533
[TBL] [Abstract][Full Text] [Related]
4. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
Noseda R; Bertoli R; Müller L; Ceschi A
J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
[TBL] [Abstract][Full Text] [Related]
5. Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study.
Diaz L; Jauzelon B; Dillies AC; Le Souder C; Faillie JL; Maria ATJ; Palassin P
J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902771
[TBL] [Abstract][Full Text] [Related]
6. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.
Zhai C; Jin X; You L; Yan N; Dong J; Qiao S; Zhong Y; Zheng Y; Pan H
BMC Geriatr; 2024 Jan; 24(1):32. PubMed ID: 38191289
[TBL] [Abstract][Full Text] [Related]
7. Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review.
Wei Y; He W; Sun W; Wu C; Ren D; Wang X; Zhang M; Huang M; Ji N
Transl Cancer Res; 2022 Aug; 11(8):2960-2966. PubMed ID: 36093533
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis.
Wang C; Sun W; Li Z; Wu T; Fang W
Invest New Drugs; 2023 Dec; 41(6):834-841. PubMed ID: 37897650
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Squamous Cell Carcinoma.
Marar R; Prathivadhi-Bhayankaram S; Krishnan M
J Hematol; 2022 Aug; 11(4):142-147. PubMed ID: 36118548
[TBL] [Abstract][Full Text] [Related]
10. Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient-A case report.
Masood A; Wahab A; Clifford T; Weaver EJ; Ehsan H; El Ayass W
Clin Case Rep; 2021 Dec; 9(12):e05184. PubMed ID: 34917381
[TBL] [Abstract][Full Text] [Related]
11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
12. Hemophagocytic Lymphohistiocytosis Secondary to PD-1 and IDO Inhibition in a Patient with Refractory Glioblastoma.
Thummalapalli R; Heumann T; Stein J; Khan S; Priemer DS; Duffield AS; Laterra J; Couzi R; Lim M; Holdhoff M
Case Rep Oncol; 2020; 13(2):508-514. PubMed ID: 32518546
[TBL] [Abstract][Full Text] [Related]
13. Encephalitis Associated With Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitors: An Unfamiliar Spin-Off.
Ghous G; Shoukat HMH; Tarar ZI; Zafar MU; McGreevy JW
Cureus; 2021 Jun; 13(6):e16079. PubMed ID: 34345559
[TBL] [Abstract][Full Text] [Related]
14. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
15. Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature.
Rubio-Perez J; Rodríguez-Perez ÁR; Díaz-Blázquez M; Moreno-García V; Dómine-Gómez M
J Med Case Rep; 2022 Oct; 16(1):365. PubMed ID: 36195892
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.
Kalmuk J; Puchalla J; Feng G; Giri A; Kaczmar J
Cancers Head Neck; 2020; 5():3. PubMed ID: 32025343
[TBL] [Abstract][Full Text] [Related]
18. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
19. Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review.
Mizuta H; Nakano E; Takahashi A; Koyama T; Namikawa K; Yamazaki N
Dermatol Ther; 2020 May; 33(3):e13321. PubMed ID: 32191382
[TBL] [Abstract][Full Text] [Related]
20. Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy.
Holmes Z; Courtney A; Hiong A
BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 35948362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
